BridgeBio to Present New Acoramidis Kidney Function Data at Amyloidosis Symposium

PUBT · 2d ago
BridgeBio to Present New Acoramidis Kidney Function Data at Amyloidosis Symposium
  • BridgeBio will present 28 acoramidis abstracts at the International Symposium on Amyloidosis in Montevideo, Uruguay, November 15-18, 2026.
  • New analyses examine kidney function in transthyretin amyloid cardiomyopathy; one finds early kidney-function changes without clinically meaningful laboratory or blood-pressure changes.
  • Real-world findings show lower initiation of transthyretin silencer therapy with acoramidis versus tafamidis, while another analysis indicates earlier reductions in heart-failure events.
  • European licensing partner Bayer will present German real-world data comparing acoramidis with tafamidis on diuretic intensification, a marker of worsening heart failure.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611110730PRIMZONEFULLFEED9874884) on November 11, 2026, and is solely responsible for the information contained therein.